ArticleFrontiers in immunology2026
Homoeriodictyol, targeting the bitter taste receptor TAS2R14, lowers the secretion of pro-inflammatory chemokines upon treatment with SARS-CoV-2 peptide pools in human peripheral blood mononuclear cells.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Excessive cytokine production is a major complication in severe COVID-19. Treatment with antiviral drugs often elicits a bitter taste through activation of bitter taste receptors (TAS2Rs). Since ectopically expressed TAS2Rs can alter cytokine secretion, we hypothesized that homoeriodictyol (HED), a broad TAS2R ligand, modulates the cytokine response to SARS-CoV-2 peptide pools (PP) in human peripheral blood mononuclear cells (PBMCs). Treatment of PBMCs isolated from healthy donors with PP for 24 h induced the mRNA expression of CXCL9, CCL7, and CCL2, the most of 116 cytokines tested. Protein release of these chemokines was quantified by ELISA after PP treatment for 3, 6, 12, 24, and 48 h. The results identified 24 h as the optimal incubation time to distinguish PP-induced chemokine release among PBMCs, T-cells, and T-cell-depleted PBMCs. PBMCs demonstrated the highest mean fold changes of CXCL9, CCL7, and CCL2 with 12, 52, and 96, respectively. Involvement of TAS2Rs was verified (i) by co-incubation of the PBMCs with PP and HED, which decreased (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.